Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

BLA PARTNERS, LLC

NPI: 1548703556 · SOUTH BURLINGTON, VT 05403 · Clinical Medical Laboratory · NPI assigned 11/22/2016

$15.14M
Total Medicaid Paid
212,298
Total Claims
93,297
Beneficiaries
11
Codes Billed
2018-01
First Month
2021-05
Last Month

Provider Details

Authorized OfficialPHILIP, CHERIAN (CFO)
NPI Enumeration Date11/22/2016

Related Entities

Other providers sharing the same authorized official: PHILIP, CHERIAN

ProviderCityStateTotal Paid
BLA OF MASSACHUSETTS, LLC WOBURN MA $1.55M

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 110,898 $8.56M
2019 57,929 $4.16M
2020 29,560 $1.68M
2021 13,911 $733K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 103,798 47,272 $8.52M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 102,038 42,712 $5.79M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 5,769 2,979 $824K
80348 393 162 $2K
80349 152 93 $682.28
80360 39 14 $268.11
80325 35 12 $254.11
80321 15 13 $154.89
80359 21 13 $85.87
80324 21 13 $85.84
81025 17 14 $0.00